Key Clinical Takeaways for Primary Care
- Alteplase or tenecteplase are both recommended within the 4.5-hour thrombolysis window
- Advanced imaging can extend thrombolysis eligibility to 9 hours or unknown onset in select patients
- EVT eligibility expands to larger infarct cores and includes strong support for basilar artery occlusion
- Intensive BP lowering (<140 mm Hg) after IVT or EVT is not recommended and may be harmful
- Tight glucose control (80–130 mg/dL) is not recommended in AIS
- Early recognition and rapid referral remain critical to improving outcomes
The 2026 guideline for early management of acute ischemic stroke (AIS) introduces updated, evidence-based recommendations that refine thrombolysis selection, expand eligibility for endovascular therapy (EVT), and revise blood pressure and glucose management strategies, with implications for frontline clinicians involved in early stroke recognition and triage.
The guideline, developed by the American Heart Association and American Stroke Association, replaces prior recommendations from 2018 and 2019 and incorporates new evidence through 2025 to guide care from prehospital evaluation through early in-hospital management.
“This update brings the most important advances in stroke care from the last decade directly into practice,” Shyam Prabhakaran, M.D., M.S., FAHA, chair of the writing group for the guideline and the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the department of neurology at the University of Chicago Medicine, said in a press release. “New recommendations in the guideline expand access to cutting-edge treatments, such as clot-removal procedures and medications, simplify imaging requirements so more hospitals can act quickly, and introduce guidance for pediatric stroke for the first time.”
Thrombolysis: Expanded Options and Timing
Intravenous thrombolysis (IVT) remains a cornerstone of AIS management, with updated guidance endorsing the use of either alteplase or tenecteplase within the standard 4.5-hour treatment window.
The guideline emphasizes rapid treatment in eligible patients with disabling neurologic deficits regardless of National Institutes of Health Stroke Scale score and without requiring advanced imaging for selection within the standard time window.
For select patients with unknown onset or those presenting 4.5 to 9 hours after symptom onset, thrombolysis may be considered using advanced imaging criteria such as diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch or perfusion-based imaging.
